Between 1976 and 1988, 31 @entity1 with mediastinal nonseminomatous @entity2971 (MNGCT) received initial @entity900 -based chemotherapy of uniform intensity. Eighteen of these @entity1 (58%) obtained disease-free status; 11 with chemotherapy alone and seven with adjunctive surgery. Eleven have remained continuously free of disease. Two have had recurrence of @entity44 and are disease-free after resection of @entity44 at 12+ and 68+ months. Three @entity1 developed recurrence of germ cell @entity5 . Three @entity1 developed a @entity1583 . Of the 18 @entity1 who obtained disease-free status, 15 remain alive and disease-free. Overall, 13 of the 31 @entity1 and 24 other @entity1 received salvage chemotherapy at Indiana University, Indianapolis, Indiana. Of these 37 @entity1 , six obtained a disease-free status and four (11%) remain alive at 13+, 56+, 78+, and 122+ months, respectively. This series represents the largest series of @entity1 with MNGCT ever reported. Analysis of these data and results from other recent series suggest that approximately 50% of @entity1 with MNGCT will be cured with modern, intense @entity900 -based chemotherapy coupled with adjunctive surgery if needed.

Primary mediastinal nonseminomatous XXXX . A modern single institution experience.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2971 :: ('MESH:D009373', 'Disease') :: ['germ cell tumors'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1583 :: ('MESH:D019337', 'Disease') :: ['hematologic malignancy'] @entity44 :: ('MESH:D013724', 'Disease') :: ['teratoma']
@entity2971 :: (MESH:D009373,Disease) :: ['germ cell tumors']
